

# Summary of Product Characteristics

## 1 NAME OF THE MEDICINAL PRODUCT

Kyleena 19.5 mg intrauterine delivery system

## 2 QUALITATIVE AND QUANTITATIVE COMPOSITION

The intrauterine delivery system contains 19.5 mg levonorgestrel.

For the full list of excipients, see section 6.1.

For details of release rates, see SmPC section 5.2 of PA1410/081/001.

## 3 PHARMACEUTICAL FORM

Intrauterine delivery system (IUS).

*Product imported from France:*

The product consists of a whitish or pale yellow drug core covered with a semi-opaque membrane, which is mounted on the vertical stem of a T-body. In addition, the vertical stem contains a silver ring located close to the horizontal arms. The white T-body has a loop at one end of the vertical stem and two horizontal arms at the other end. The blue coloured removal threads are attached to the loop. The vertical stem of the IUS is loaded in the insertion tube at the tip of the inserter. The inserter consists of a handle and slider that are integrated with flange, lock, pre-bent insertion tube and plunger. The removal threads are located within the insertion tube and handle.

Dimensions of Kyleena: 28 x 30 x 1.55 mm

## 4 CLINICAL PARTICULARS

As per PA1410/081/001

## 5 PHARMACOLOGICAL PROPERTIES

As per PA1410/081/001

## 6 PHARMACEUTICAL PARTICULARS

### 6.1 List of excipients

Polydimethylsiloxane elastomer  
Silica, colloidal anhydrous  
Polyethylene  
Barium sulfate  
Polypropylene  
Copper phthalocyanine  
Silver

### 6.2 Incompatibilities

Not applicable.

### 6.3 Shelf life

The shelf-life expiry date of this product shall be the date shown on the blister package and outer package of the product on the market in the country of origin.

#### **6.4 Special precautions for storage**

This medicinal product does not require any special storage conditions.

#### **6.5 Nature and contents of container**

The product is individually packed into a thermoformed blister package (PETG) with a peelable lid (PE). Pack sizes: 1x1.

#### **6.6 Special precautions for disposal and other handling**

The product is supplied in a sterile package which should not be opened until required for insertion. Each system should be handled with aseptic precautions. If the seal of the sterile envelope is broken, the system inside should be disposed of in accordance with local guidelines for the handling of biohazardous waste. Likewise, a removed Kyleena and inserter should be disposed of in this manner.

To be inserted by a healthcare professional using aseptic technique (see SmPC section 4.2 of PA1410/081/001).

Any unused medicinal product or waste material should be disposed of in accordance with local requirements. This medicinal product may pose a risk to the environment (see SmPC section 5.3 of PA1410/081/001).

### **7 PARALLEL PRODUCT AUTHORISATION HOLDER**

IMED Healthcare Ltd,  
Unit 625 Kilshane Avenue,  
Northwest Business Park,  
Ballycoolin,  
Dublin 15,  
Ireland

### **8 PARALLEL PRODUCT AUTHORISATION NUMBER**

PPA1463/186/001

### **9 DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION**

Date of first authorisation: 25<sup>th</sup> February 2022

### **10 DATE OF REVISION OF THE TEXT**